NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback